Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1052)	7/4/1999 10:16:00 PM
From: William Strop	Read Replies (1) \| Respond to of 1972

Scott, Here is the start of the Malaria Phase I results press release.. ******** VICAL AND U.S. NAVY DEMONSTRATE DNA VACCINE TECHNOLOGY IN MAN Trial Results for Novel Malaria Vaccine Published in Science WASHINGTON, D.C.—October 15, 1998—In the October 16, 1998, issue of Science, researchers report the first demonstration of safety and "killer" cytotoxic T lymphocyte (CTL) immune responses in healthy human volunteers of a novel "naked" DNA vaccine technology. Scientists from the Naval Medical Research Center (NMRC), Vical Incorporated (Nasdaq:VICL), the U.S. Army Medical Research Institute of Infectious Diseases, and Pasteur Mérieux Connaught (Rhône-Poulenc Group) report that the majority of 20 subjects immunized with a potential malaria DNA vaccine developed CTL responses, and that the responses were dose-related. ********** I have a question... Does overbought mean anything in a market like we have seen over the past several years??? Bill